Skip to main content
SpringerLink
Log in

Resectable and Borderline Resectable Pancreatic Cancer

  • Chapter
  • First Online:
Book cover Gastrointestinal Malignancies

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 1122 Accesses

Abstract

The standard treatment for resectable pancreatic cancer continues to evolve, and controversy remains regarding the role of radiation. Surgery followed by adjuvant treatments results in disappointing outcomes. Neoadjuvant therapy has several potential advantages over adjuvant therapy including earlier delivery of systemic treatment, in vivo assessment of response, increased resectability rate in borderline resectable patients, and increased margin-negative resection rate. Radiation and chemoradiation have been incorporated into neoadjuvant and adjuvant strategies, especially with the development of newer technologies and improved radiotherapy techniques capable of safely delivering intensified therapy with alternative fractionation regimens. This chapter provides a guide for treatment planning for radiation-containing treatment strategies incorporating radiation for resectable and borderline resectable pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Griffin JF, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66(1):56–61.

    Article  CAS  PubMed  Google Scholar 

  2. Sohn TA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–79.

    Article  CAS  PubMed  Google Scholar 

  3. Neoptolemos JP, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.

    Article  CAS  PubMed  Google Scholar 

  4. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  5. Poplin E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol. 2009;27(23):3778–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Evans DB, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496–502.

    Article  CAS  PubMed  Google Scholar 

  7. Hoffman JP, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an eastern cooperative oncology group study. J Clin Oncol. 1998;16(1):317–23.

    Article  CAS  PubMed  Google Scholar 

  8. White RR, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8(10):758–65.

    Article  CAS  PubMed  Google Scholar 

  9. Moutardier V, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004;60(2):437–43.

    Article  PubMed  Google Scholar 

  10. Palmer DH, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14(7):2088–96.

    Article  PubMed  Google Scholar 

  11. Laurence JM, et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15(11):2059–69.

    Article  PubMed  Google Scholar 

  12. Varadhachary GR, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487–95.

    Article  CAS  PubMed  Google Scholar 

  13. Hosein PJ, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Satoi S, et al. Long-term results of surgical resection after preoperative chemoradiation in patients with pancreatic cancer. Pancreas. 2012;41(2):333–5.

    Article  PubMed  Google Scholar 

  15. Klinkenbijl JH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 782-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Neoptolemos JP, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.

    Article  CAS  PubMed  Google Scholar 

  17. Gillen S, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Vauthey JN, Dixon E. AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol. 2009;16(7):1725–6.

    Article  PubMed  Google Scholar 

  19. Katz MH, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.

    Article  PubMed  PubMed Central  Google Scholar 

  20. National Comprehensive Cancer Network (NCCN) Guidelines. V 1.2016, (PancreaticAdenocarcinoma). 2016. (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site).

  21. Varadhachary GR, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.

    Article  PubMed  Google Scholar 

  22. Katz MH, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46. discussion 846-8

    Article  PubMed  Google Scholar 

  23. Callery MP, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.

    Article  PubMed  Google Scholar 

  24. Abrams RA, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751–6.

    Article  PubMed  Google Scholar 

  25. Evans DB, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.

    Article  CAS  PubMed  Google Scholar 

  26. Oettle H, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  27. Pancreatic cancer survival increases with Chemo Combo. Cancer Discov. 2016;6(8):OF3.

    Google Scholar 

  28. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.

    Article  CAS  PubMed  Google Scholar 

  29. Herman JM, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503–10.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Corsini MM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26(21):3511–6.

    Article  PubMed  Google Scholar 

  31. Hsu CC, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Regine WF, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26.

    Article  CAS  PubMed  Google Scholar 

  33. Van Laethem JL, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28(29):4450–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Merrell KW, et al. Predictors of Locoregional failure and impact on overall survival in patients with resected exocrine pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):561–70.

    Article  PubMed  Google Scholar 

  35. Abelson JA, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012;82(4):e595–601.

    Article  PubMed  Google Scholar 

  36. Ben-Josef E, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1166–71.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Nichols RC Jr, et al. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):158–63.

    Article  PubMed  Google Scholar 

  38. Crane CH, Beddar AS, Evans DB. The role of intraoperative radiotherapy in pancreatic cancer. Surg Oncol Clin N Am. 2003;12(4):965–77.

    Article  PubMed  Google Scholar 

  39. Zerbi A, et al. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer. 1994;73(12):2930–5.

    Article  CAS  PubMed  Google Scholar 

  40. Alfieri S, et al. Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch Surg. 2001;136(3):343–7.

    Article  CAS  PubMed  Google Scholar 

  41. Reni M, et al. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2001;50(3):651–8.

    Article  CAS  PubMed  Google Scholar 

  42. Ogawa K, et al. Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):734–42.

    Article  PubMed  Google Scholar 

  43. Valentini V, et al. Intraoperative radiation therapy in resected pancreatic carcinoma: long-term analysis. Int J Radiat Oncol Biol Phys. 2008;70(4):1094–9.

    Article  PubMed  Google Scholar 

  44. Showalter TN, et al. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol. 2009;16(8):2116–22.

    Article  PubMed  Google Scholar 

  45. Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol. 1999;10(Suppl 4):226–30.

    Article  PubMed  Google Scholar 

  46. Artinyan A, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117(10):2044–9.

    Article  PubMed  Google Scholar 

  47. Van Buren G II, et al. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2013;20(12):3787–93.

    Article  PubMed  Google Scholar 

  48. Motoi F, et al. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;21(2):148–58.

    Article  PubMed  Google Scholar 

  49. Heinrich S, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526–31.

    Article  CAS  PubMed  Google Scholar 

  50. Andriulli A, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644–62.

    Article  PubMed  Google Scholar 

  51. Pisters PW, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16(12):3843–50.

    Article  CAS  PubMed  Google Scholar 

  52. Pisters PW, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20(10):2537–44.

    Article  CAS  PubMed  Google Scholar 

  53. Breslin TM, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8(2):123–32.

    Article  CAS  PubMed  Google Scholar 

  54. Greer SE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg. 2008;206(3):451–7.

    Article  PubMed  Google Scholar 

  55. Willett CG, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993;217(2):144–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Papalezova KT, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106(1):111–8.

    Article  PubMed  Google Scholar 

  57. Chandler NM, et al. Preoperative chemoradiation in resectable pancreatic cancer. J Hepato-Biliary-Pancreat Surg. 2003;10(1):61–6.

    Google Scholar 

  58. Evans DB. Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. J Gastrointest Surg. 2001;5(1):2–5.

    Article  CAS  PubMed  Google Scholar 

  59. Sahora K, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery. 2011;149(3):311–20.

    Article  PubMed  Google Scholar 

  60. Sahora K, et al. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35(7):1580–9.

    Article  PubMed  Google Scholar 

  61. Boone BA, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108(4):236–41.

    Article  CAS  PubMed  Google Scholar 

  62. Faris JE, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital cancer Center experience. Oncologist. 2013;18(5):543–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ferrone CR, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Nanda RH, et al. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015;111(8):1028–34.

    Article  CAS  PubMed  Google Scholar 

  65. Petrelli F, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015;44(4):515–21.

    Article  CAS  PubMed  Google Scholar 

  66. Landry J, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Massucco P, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13(9):1201–8.

    Article  PubMed  Google Scholar 

  68. Mehta VK, et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol. 2001;24(2):155–9.

    Article  CAS  PubMed  Google Scholar 

  69. Patel M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011;104(2):155–61.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Small W Jr, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008;26(6):942–7.

    Article  CAS  PubMed  Google Scholar 

  71. Stokes JB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27.

    Article  PubMed  Google Scholar 

  72. Huguet F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25(3):326–31.

    Article  CAS  PubMed  Google Scholar 

  73. Kim EJ, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Krishnan S, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110(1):47–55.

    Article  PubMed  Google Scholar 

  75. Leone F, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119(2):277–84.

    Article  CAS  PubMed  Google Scholar 

  76. Mukherjee S, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Pipas JM, et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012;23(11):2820–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Polistina F, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010;17(8):2092–101.

    Article  PubMed  Google Scholar 

  79. Shinchi H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2002;53(1):146–50.

    Article  CAS  PubMed  Google Scholar 

  80. Tinkl D, et al. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol. 2009;185(9):557–66.

    Article  PubMed  Google Scholar 

  81. Hsiung-Stripp DC, et al. Comparative treatment planning between proton and X-ray therapy in pancreatic cancer. Med Dosim. 2001;26(3):255–9.

    Article  CAS  PubMed  Google Scholar 

  82. Kozak KR, et al. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys. 2007;68(5):1557–66.

    Article  PubMed  Google Scholar 

  83. Bouchard M, et al. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol. 2009;92(2):238–43.

    Article  PubMed  Google Scholar 

  84. Lee RY, et al. Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers. J Gastrointest Oncol. 2013;4(4):374–9.

    PubMed  PubMed Central  Google Scholar 

  85. Ding X, et al. A comprehensive dosimetric study of pancreatic cancer treatment using three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), volumetric-modulated radiation therapy (VMAT), and passive-scattering and modulated-scanning proton therapy (PT). Med Dosim. 2014;39(2):139–45.

    Article  PubMed  Google Scholar 

  86. Thompson RF, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41(8):081711.

    Article  PubMed  Google Scholar 

  87. Nichols RC Jr, et al. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol. 2013;52(3):498–505.

    Article  CAS  PubMed  Google Scholar 

  88. Hong TS, et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011;79(1):151–7.

    Article  CAS  PubMed  Google Scholar 

  89. Hong TS, et al. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;89(4):830–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Wo JY, et al. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol. 2014;110(1):160–4.

    Article  CAS  PubMed  Google Scholar 

  91. Keane FK, et al. Intraoperative radiotherapy in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma. Am J Clin Oncol. 2016.

    Google Scholar 

  92. Chang DT, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665–72.

    Article  PubMed  Google Scholar 

  93. Herman JM, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–37.

    Article  CAS  PubMed  Google Scholar 

  94. Chuong MD, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516–22.

    Article  PubMed  Google Scholar 

  95. Rosati L, et al. The role of neoadjuvant stereotactic body radiation therapy in pancreatic cancer. American Radium Society. Dent Abstr. 2015:S021.

    Google Scholar 

  96. Reese AS, Lu W, Regine WF. Utilization of intensity-modulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Semin Radiat Oncol. 2014;24(2):132–9.

    Article  PubMed  Google Scholar 

  97. Mori S, et al. Four-dimensional measurement of intrafractional respiratory motion of pancreatic tumors using a 256 multi-slice CT scanner. Radiother Oncol. 2009;92(2):231–7.

    Article  PubMed  Google Scholar 

  98. Heinzerling JH, et al. Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Radiat Oncol. 2011;6:146.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Khashab MA, et al. Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointest Endosc. 2012;76(5):962–71.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Gwynne S, et al. Respiratory movement of upper abdominal organs and its effect on radiotherapy planning in pancreatic cancer. Clin Oncol (R Coll Radiol). 2009;21(9):713–9.

    Article  CAS  Google Scholar 

  101. Goldstein SD, et al. Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2010;76(2):597–602.

    Article  PubMed  Google Scholar 

  102. Abrams RA, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704—a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012;82(2):809–16.

    Article  CAS  PubMed  Google Scholar 

  103. Bekelman JE, et al. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials—report of the National Cancer Institute work group on radiotherapy quality assurance. Int J Radiat Oncol Biol Phys. 2012;83(3):782–90.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Chavaudra J, Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Cancer Radiother. 2001;5(5):472–8.

    Article  CAS  PubMed  Google Scholar 

  105. Whitfield G, et al. Quantifying motion for pancreatic radiotherapy margin calculation. Radiother Oncol. 2012;103(3):360–6.

    Article  PubMed  Google Scholar 

  106. Bentzen SM, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S1–160.

    Google Scholar 

  107. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9. doi:10.1016/j.ijrobp.2009.07.1754.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford Cancer Institute, Palo Alto, CA, USA

    Diego A. S. Toesca M.D., Daniel T. Chang M.D. & Albert C. Koong M.D., Ph.D.

  2. University of Washington, Seattle, WA, USA

    Edward Kim M.D.

  3. MD Anderson Cancer Center, Houston, TX, USA

    Joseph Herman M.D.

  4. Case Western Reserve University School of Medicine, Cleveland, OH, USA

    Suzanne Russo M.D.

Authors
  1. Diego A. S. Toesca M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel T. Chang M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Kim M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph Herman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Albert C. Koong M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suzanne Russo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio, USA

    Suzanne Russo

  2. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA

    Sarah Hoffe

  3. Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington, USA

    Edward Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Toesca, D.A.S., Chang, D.T., Kim, E., Herman, J., Koong, A.C., Russo, S. (2018). Resectable and Borderline Resectable Pancreatic Cancer. In: Russo, S., Hoffe, S., Kim, E. (eds) Gastrointestinal Malignancies. Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-64900-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64900-9_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64899-6

  • Online ISBN: 978-3-319-64900-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation